Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907

RELATED NEWS
Trade CRIS now with 

Curis Inc. (CRIS: Quote) announced the presentation of data in a poster session at the American Association for Cancer Research or AACR Annual Meeting 2012 in Chicago, Illinois.

The poster presentation, titled "Antitumor Activity of CUDC-907, a Dual PI3K and HDAC Inhibitor in Hematological Cancer Models", was presented by Rudi Bao, M.D., Ph.D., Curis' Senior Director of Oncology.

The company noted that the poster presentation focused on CUDC-907's biologic activity in cell culture and animal models of various hematological cancers, with a particular focus on multiple myeloma and B-cell lymphoma. In in vitro and in vivo testing, CUDC-907 outperformed a first-in-class HDAC inhibitor as well as an investigational pan-PI3K (Class I) inhibitor given as a single agent or in a combination of both agents.

CUDC-907 also demonstrated enhanced antitumor activity in animal models of B-cell lymphoma and multiple myeloma when co-administered with standard of care agents used in the treatment of patients with these malignancies.

Furthermore, this poster showed that many commonly used in vivo models of B-cell lymphoma and multiple myeloma expressed various PI3K Class I isoforms, suggesting that a pan-PI3K inhibitor such as CUDC-907 may be of greater benefit in many cases than a PI3K inhibitor that is focused narrowly on one PI3K isoform.

The company stated that CUDC-907 showed greater biologic activity than a delta-specific investigational inhibitor in a number of hematological cancer cells in vitro, and showed greater growth-inhibitory activity in an animal model of non-Hodgkin's Lymphoma.

Register
To receive FREE breaking news email alerts for Curis Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Colorado based doctor Dilip Joseph, who was kidnapped by the Taliban discusses his ordeal in detail in a book published by Amazon on Tuesday. Extending the rebound seen over the course of the previous session, stocks moved sharply higher during trading on Friday. The gains on the day partly offset the recent sell-off on Wall Street, although the major averages remain well off their mid-September highs. While the Ebola outbreak in the U.S. has thus far been limited to just three people, the results of a new CBS News poll suggest that news of the disease has contributed to a sharp drop in public confidence in the Centers for Disease Control and Prevention.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.